783 related articles for article (PubMed ID: 20684148)
1. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
3. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
4. Etanercept for psoriasis in the pediatric population: experience in nine patients.
Hawrot AC; Metry DW; Theos AJ; Levy ML
Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
6. Managing pediatric patients with psoriasis.
Bard S; Torchia D; Schachner LA
Am J Clin Dermatol; 2010; 11 Suppl 1():15-7. PubMed ID: 20586500
[TBL] [Abstract][Full Text] [Related]
7. The evolving role of biologics in the treatment of pediatric psoriasis.
Luu M; Cordoro KM
Skin Therapy Lett; 2013 Feb; 18(2):1-4. PubMed ID: 23508772
[TBL] [Abstract][Full Text] [Related]
8. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
10. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
11. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
Weisman MH
J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
13. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
15. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy in psoriasis: perspectives on associated risks and patient management.
Papp KA; Dekoven J; Parsons L; Pirzada S; Robern M; Robertson L; Tan JK
J Cutan Med Surg; 2012; 16(3):153-68. PubMed ID: 22713438
[TBL] [Abstract][Full Text] [Related]
18. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
19. From conventional to cutting edge: the new era of biologics in treatment of psoriasis.
Tzu J; Kerdel F
Dermatol Ther; 2008; 21(2):131-41. PubMed ID: 18394087
[TBL] [Abstract][Full Text] [Related]
20. Biologic survival.
Noiles K; Vender R
J Drugs Dermatol; 2009 Apr; 8(4):329-33. PubMed ID: 19363851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]